Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) is characterized by increased pulmonary permeability with high mortality. Resolvin D1 (RvD1), which has potent anti-inflammatory and pro-resolving activity, can attenuate pulmonary edema in the animal model of ALI. However, the mechanism underlying the protection of RvD1 on pulmonary edema is still unknown. Here we explore the effects and mechanism of RvD1 on the disruption of tight junction protein that results in the permeability edema in a model of lipopolysaccharide (LPS)-induced ALI. The severity of pulmonary edema was assessed by wet-to-dry rate and Evans blue infiltration; expressions of tight junction (TJ) proteins occludin and zona occludin-1 (ZO-1) were examined by immunofluorescence staining and western blot; mRNA in lung tissue was studied by real time-PCR; the TUNEL kit was performed for the detection of apoptosis of pulmonary barrier. Twenty-four hours after LPS inhalation by mice, wet-to-dry rate and Evans blue infiltration indicated that pretreatment with RvD1 relieved the pulmonary edema and pulmonary capillary permeability. Moreover, RvD1 attenuated the LPS-induced deterioration of TJ protein ZO-1 and occludin significantly. And we found that RvD1 increased heme oxygenase-1 (HO-1) expression contributed to the protection on the deterioration of TJs. In addition, we found that RvD1 could reduce pulmonary cellular apoptosis in LPS-induced mice. In conclusion, RvD1 possesses the ability that relieves the pulmonary edema and restores pulmonary capillary permeability and reduces disruption of TJs in LPS-induced ALI of mice, at least in part, by upregulating HO-1 expression.
Acute lung injury (ALI) is still a severe clinical problem with a high mortality despite significant advances in antimicrobial therapy and supportive care made in the past few years. 1 An important character of ALI is edema, which is due to the disruption of the paracellular alveolar barrier. 2 Tight junction (TJ) proteins create a regulated paracellular barrier to the movement of water, solutes, and immune cells between both epithelial and endothelial cells. 3 It has previously been demonstrated that alveolar epithelial cells express occludin and zona occludin-1 (ZO-1) as part of the TJ complex. 3, 4 The trans-membrane protein occludin is an excellent candidate for the sealing protein and is bound on the cytoplasmic membrane surface to the proteins ZO-l and ZO-2. 3 In addition, both apoptosis of endothelial and epithelial cells and dysfunction of TJ proteins can introduce pulmonary barriers disruption and cause edema during the ALI. 5 Most important is that no standard treatment exists for permeability edema, making the research for restoring endothelial and epithelial hyper-permeability important. Resolvin D1 (RvD1) is a novel lipid mediator identified in resolving inflammation that was enzymatically derived from docosahexaenoic acid (DHA). DHA-derived resolvins act as a cytoprotective mechanism against oxidant injury 6, 7 and the pro-resolving mediators, eg, lipoxin A4 and resolvins, can return the permeability/edema to normal. 8 Previous studies have showed that RvD1 displays potent anti-oxidative stress, 9 anti-inflammation, and pro-resolving actions that have been demonstrated in mouse models of ALI. [10] [11] [12] Though they have been observed that RvD1 can reduce pulmonary edema induced by lipopolysaccharide (LPS), the effects of RvD1 on TJ protein remain elusive.
LPS, an endotoxin that resides on the outer membrane of Gram-negative bacteria, is known to enhance the formation of reactive oxygen species (ROS), inflammatory mediators, and promotes oxidative stress. 13 ROS and inflammatory mediators triggers significant disruption of TJ proteins resulting in increased pulmonary permeability. 5, 14 In this study, we test the hypothesis that RvD1 relieves permeability edema in LPS-induced mice by reduces disruption of TJ proteins. As a result, the deterioration of ZO-1 and occludin in mice exposed to LPS was attenuated by pretreatment with RvD1, which was reversed by a heme oxygenase-1 (HO-1) inhibitor.
MATERIALS AND METHODS
Reagents LPS was purchased from Sigma (St Louis, MO, USA). RvD1 was from Cayman (Ann Arbor, MI, USA). The integrity of RvD1 was assured by monitoring the physical properties with High Performance Liquid Chromatography (HPLC) just before evaluating their biological activities. Zinc Protoporphyrin-9 (Znpp IX) was from (Enzo Life Sciences). GAPDH antibodies were purchased from Cell Signaling Technology (Boston, MA, USA). Mouse HO-1 antibody was from Abcam (Cambridge, MA, USA). Occludin and ZO-1 antibodys were purchased from Invitrogen (Frederick, MD, USA). Horseradish peroxidase-conjugated goat anti-rabbit antibody, bicinchoninic acid (BCA) protein assay kit and enhancer chemiluminescent (ECL) reagent were obtained from Pierce Biotechnology (Rockford, IL, USA). Protein extraction kit and TUNEL in situ apoptosis detection kit was from Key GEN Bio TECH.
Animals
Male Balb/c-mice (8-10 weeks old; weight range, 25-30 g) were obtained from Guangdong Medical Laboratory Animal Center (Guangdong, PR China). All mice received humane care according to the guidelines of the Local Institutes of Health guide for the care and use of laboratory animals. Mice were housed in a specific pathogen-free laboratory under optimum conditions (25 1C, 55% humidity and 12 h day/night rhythm) and fed with a standard laboratory diet and water. They were acclimatized for at least 1 week before use. All experimental procedures involving animals were approved by the Animal Care and Use Committee of Tongji Medical College in Huazhong University of Science and Technology.
Experimental Protocols ALI was performed as described before. 15 Briefly, animals were anesthetized with ketamine (30 mg/kg) intraperitoneally (i.p.). Sterile saline solution containing LPS was placed after intubation and aspirated into the lungs (3.0 mg/kg). Sixty mice were randomly assigned to six groups: (a) control
, (e) LPS þ 5 mg/kg RvD1 þ 50 mg/ kg Znpp (n ¼ 10), and (f) LPS þ 50 mg/kg Znpp (n ¼ 10). Znpp was dissolved in 100% dimethyl sulfoxide (Calbiochem) and injected i.p. 1 h before administration of LPS. Then, RvD1 diluted in 0.9% sterile saline solution or vehicle (0.9% endotoxin-free saline) was injected though caudal vein 30 min before LPS administration. Mice (n ¼ 10) were humanely killed at 24 h after LPS administration; the lung tissues were used for further analysis. Another 40 mice were randomly assigned to four groups: (a) control (n ¼ 10), (b) LPS (n ¼ 10), (c) LPS þ RvD1 (n ¼ 10), and (d) RvD1 (n ¼ 10). Each groups (a, b, c, and d) were injected Evans blue dye (EB; 2%; 5 ml/kg; Sigma, St Louis, MO, USA) for permeability analysis.
Hematoxylin and Eosin (HE) Staining
Lung samples were obtained at 24 h after LPS administration. Tissues were fixed in 4% paraformaldehyde and subsequently embedded in paraffin. Sections were stained with HE using a standard protocol and analyzed by light microscopy.
Lung Wet/Dry Weight Ratio
The lungs were dissected, weighed, and dried in an oven at 60 1C for 5 days. Then the W/D ratio was calculated by dividing the wet weight by the final dry weight.
EB
To further assess lung permeability, EB was dissolved in 0.9% saline at a final concentration of 5 mg/ml. Animals were anesthetized, weighed, and injected with 20 mg/kg EB in the vein. After 30 min, the animals were killed and the lungs perfused with 1 ml PBS containing 5 mM EDTA. The lungs were collected and frozen in liquid N 2 . The frozen lungs were homogenized in 2 ml PBS. The homogenate was diluted with two volume of formamide and incubated at 60 1C for 2 h, followed by centrifugation at 5000 g for 30 min. The supernatant was collected and absorbance was measured at 650 nm in a spectrophotometer. The EB concentration was determined from the standard absorbance curves evaluated in parallel. Correction for contaminating heme dye was calculated. The EB concentration was expressed as a percentage of the total dose of EB administered as described earlier. 16 
Immunofluorescence Microscopy
The microwave antigen repair technique was used to improve occludin and ZO-1-positive detection rate. Slides were placed in a plastic Coplin jar, filled with citrate buffer (pH 6.0), and covered with perforated cling film to minimize evaporation. Coplin jars were placed, evenly spaced, in a domestic microwave oven and irradiated for 5 min at medium power. After microwave irradiation, the slides were allowed to cool to room temperature and washed with PBS (pH 7.4) for 5 min 3 Â . The sections were then blocked with 10% goat serum RvD1 reduces deterioration of TJ proteins W Xie et al for 30 min at 37 1C and incubated with primary antibodies with antibodies directed against occludin (Rabbit antiOccludin (C-term), 1:100; Invitrogen) and ZO-1 (rabbit IgG, 1:100; Invitrogen). Samples were incubated with primary antibodies at 4 1C overnight and then the second antibody with biotin for 30 min at room temperature. After drying, samples were conjugated with SABC complex SABC-CY3/ (red fluorescence) for 30 min at room temperature. Before any step, there must be sufficient washes with PBS for 3 min 3 Â , and all the incubation must be done in wet box. Images were captured by confocal laser scanning microscopy (Eclipse 80i, Nikon, Japan).
Real-Time-PCR
Differential expression of occludin and ZO-1 was validated by a separate comparison of new subjects using real-time-PCR. RNA was extracted (Invitrogen, Camarillo, Calif, USA) following the manufacturer's instructions. The cDNA was generated from 1 mg total of each sample (SuperScript III; Invitrogen). The sequences of following primers were designed by Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, California) and are shown in Table 1 . Relative gene expression was calculated by the 2 À DDCT method.
Western Blot Assays
The proteins of samples were prepared according to the method described by the protein extract kit. Proteins concentrations were determined by the BCA protein assay kit (Piece Biotechnology, Rockford, USA). In all, 50-mg proteins extracts were fractionated on 8% polyacrylamidesodiumdodecyl sulfate gel and then transferred to PVDF membrane. The membrane was blocked with 5% (w/v) fatfree milk in Tris-buffered saline containing 0.05% Tween 20 for 2 h, followed by incubation with rabbit primary polyclonal antibodies, including anti-occludin (1:150), ZO-1 (1:250), HO-1 (1:200), and anti-GAPDH (1:2000) at 4 1C overnight. After washing three times, membranes were incubated with the horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:40 000) secondary antibody for 1 h at room temperature. The immune active bands were detected with ECL chemiluminescence detection kits (Thermo), followed by exposure to Kodakx-ray film (Kodak, Japan). The bands were quantified densitometrically as arbitrary volume integration units using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). Results were corrected for the internal standard GAPDH. The Evans blue dye in lung comparing with the total dose injected (EB lung/EB total) was used to assess lung extravascular permeability. LPS significantly increased the W/D ratio of lung weight and the Evans blue infiltration, which was attenuated by pretreatment with RvD1. The data were presented as mean ± s.e.m.; (n ¼ 10). *Po0.05, **Po0.01 versus control group; ## Po0.01 versus LPS group.
TUNEL Assay
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RESULTS
Effect of RvD1 on LPS-Induced Pathological Changes of Lung Tissue
To determinate whether RvD1 exhibits protection on LPS-induced ALI, RvD1 was administrated 30 min before LPS challenge. HE staining was used to show pathological changes. There were no pathological changes in the lung tissue of control group (Figure 1a) . In contrast, in the lung tissues of LPS group mice, significant infiltration of inflammatory cells, extensive thickening of the alveolar wall, demolished structure of pulmonary alveoli, and hemorrhage were observed at 24 h after LPS installation (Figure 1b) . Pretreatment with RvD1 markedly alleviated LPS-induced pathological changes of lung (Figure 1c) . The group pretreated with only RvD1 did not show any difference with the control group (Figure 1d ).
Effect of RvD1 on LPS-Induced Pulmonary Edema and Vascular Permeability
The W/D ratio and extravasation of EB in the lung tissue were significantly elevated in the LPS group compared with the control group (Figure 2a and b) , suggesting that LPS induced significant disruption of the pulmonary capillary barrier and elevation of pulmonary capillaries permeability. Notably, pretreatment with RvD1 attenuated pulmonary capillaries permeability in LPS-induced mice: the W/D ratio was reduced (Figure 2a ) and the amount of EB leakage was diminished (Figure 2b ).
Effect of RvD1 on LPS-Induced Disruption of TJ Proteins
To determine whether elevation of pulmonary capillaries permeability in LPS-induced mice is the result of disruption of TJ proteins ZO-1 and occludin, western blot analysis and immunofluorescence were used. Our results found that exposure to LPS markedly reduced the protein expression of ZO-1 and occludin in the lung tissue compared with the control group, which was blunted by pretreatment with RvD1 significantly. In addition, only administration of RvD1 without LPS did not result in any significant change of TJ proteins ZO-1 and occludin in lung tissue ( Figure 3 ).
Effect of RvD1 on LPS-Enhanced Expression of HO-1 in Lung Tissue
LPS binds to Toll-like receptor 4 initiating pro-inflammatory mediators and excessive ROS, which is associated with the disruption of TJ proteins. HO-1 has an important role in Figure 3 Effect of RvD1 on the protein expression of ZO-1 and occludin in lungs. Immunofluorescenece and western blot analysis were performed to detect the expression of tight junction proteins ZO-1 and occludin in lung tissue. (a) Twenty-four hours after exposure of LPS to mice, the expression of ZO-1 and occludin was dramatically reduced in lung tissues, which was attenuated by pretreatment with RvD1. GAPDH was used to show the equal loading volume. Protein expression/GAPDH was used to show the relative expression. Data were presented as mean ± s.e.m.; (n ¼ 10). *Po0.05, **Po0.01 versus control group; # Po0.05, ## Po0.01 versus LPS group. (b) The results of immunostaining showed that ZO-1 and occludin stain diffusely in normal lung tissue, which was disrupted by exposure to LPS. And RvD1 restored the tight junction protein distribution (n ¼ 10).
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W Xie et al protecting lung tissue from injury induced by ROS. To determine whether HO-1 signal is involved in the protective effects of RvD1, a special inhibitor of heme oxygenase, Zinc Protoporphyrin-9 (Znpp IX), was exposed to mice before treatment with RvD1. We evaluated the protein and mRNA expression of HO-1 in each group. Both protein and mRNA expression of HO-1 were increased after treatment with LPS, which was enhanced by pretreatment with RvD1, and pretreatment with Znpp blocked the expression of HO-1 induced by LPS (Figure 4a, b and c) . Subsequently, we evaluated the pathological change after challenge with Znpp and found that exposure to Znpp reversed the protection of RvD1 on pulmonary injury induced by LPS, which was consistent with the expression of HO-1 (Figure 4d ).
HO-1-Mediated RvD1 Protection on LPS-Induced Disruption of TJ
To detect whether HO-1 devotes to protection of RvD1 on disruption of TJs induced by LPS, we used RT-PCR and western blot to analysis the expressions of ZO-1 and occludin. Results showed that Znpp can sharply attenuate the effect of RvD1 on protecting TJ proteins from disruption ( Figure 5 ), suggesting that HO-1 mediated RvD1 protection on LPS-induced lung injury and TJ protein disruption.
Effect of RvD1 on LPS-Induced Pulmonary Cell Apoptosis
Considering that pulmonary cell apoptosis is another important pathophysiological process of elevation of pulmonary capillary permeability in LPS-exposed mice, we evaluated the RvD1 effects on LPS-induced pulmonary cell apoptosis. Our results found that LPS resulted in a marked increase in the proportion of TUNEL-positive apoptotic cells in the lung tissue relative to the control group. The LPS-induced apoptosis was profoundly reduced in the presence of RvD1, which was abrogated by Znpp ( Figure 6 ). 
DISCUSSION
Although excessive edema and hyper pulmonary capillary permeability in ALI and its most severe form ARDS has been realized for many years, there are still no effective therapeutic agents. 17, 18 RvD1, which possesses anti-inflammatory and pro-resolving ability in many process of inflammatory resolution, has demonstrated that it can attenuate inflammatory responses in ALI, 10, 11 peritonitis, 19, 20 kidney ischemia-reperfusion injury, 21 and retinopathy. 22 Here our study was focused on the effects of RvD1 on disruption of pulmonary barrier in ALI and was undertaken to investigate possible molecular and cellular mechanism of RvD1. Our results showed that the effect of 5 mg/kg RvD1 is potent, which is in accordance with the previous experiment. 10 Our present data provide the evidence that RvD1 restores increased pulmonary permeability induced by LPS in vivo, which is via preventing deterioration of ZO-1 and occludin. It has been shown that LPS-induced inflammation is linked to increased pulmonary permeability; 23 our result confirmed that administration of LPS resulted in ALI, characterized by pulmonary edema in interstitium and alveolous, and demolished structure of pulmonary alveoli and hypervascular permeability. There are two pathways in lung tissue that allow solutes to traverse the barriers: trans-cellular and paracellular. 24, 25 TJs serve the major functional purpose of providing a 'barrier' and a 'fence' within the membrane, by regulating paracellular permeability and maintaining cell polarity. Occludin is expressed in the TJs of endothelial cells and epithelial cells and requires the co-expression of junction protein ZO-1 for cell surface expression. 4, 26 Our study, for the first time, demonstrated that RvD1 can reduce deterioration of TJ protein ZO-1 and occludin in LPS-induced mice by using western blot and immunofluorescence staining, which is at least one reason which can explain that RvD1 can relieve pulmonary edema, reduce wet-to-dry rate, and EB infiltration.
There are many factors that can influence TJ, such as infection, 27, 28 cytokines, 29 and ROS. 30, 31 In the pathogenesis of ALI, extensive cytokines and ROS were released. 32 Inflammation initiated by oxidative stress can be regulated by the RvD1. 9 One of our previous studies on 15-epi-16-parafluorophenoxy lipoxin A4 (ATL), an analogue of RvD1, have found that ATL not only increased HO-1 expression but also markedly diminished all markers of lung injury. 33 In addition, ATL-1 induces HO-1 in human endothelial cells, revealing an undescribed mechanism for the antiinflammatory activity of these lipid mediators. 34 Another study has discovered that protectin D1 regulates HO-1 in a renal model. 35 HO-1, which is a rate-limiting enzyme that metabolizes heme accumulates in tissues because of blood red cell turnover, is correlated with the production of ROS. 36 Against this background, our purpose was to find out whether RvD1 can protect TJ proteins from disruption by Regulation of HO-1 activity as an adaptive response to oxidative stress is to ameliorate the effects of many oxidative stressors. 37 When pretreated with RvD1, mice that inhaled LPS had a high transcription and protein expression of HO-1. Znpp, which competes with the natural heme substrate, is considered to be a potent inhibitor of HO-1 activity. In the research, Znpp reduced the mRNA and protein amount of HO-1 compared with the LPS þ RvD1 group and LPS group while the pathology revealed that lung injury became more serious after Znpp was injected. Besides, most important is that the expression of occludin and ZO-1 in the LPS þ RvD1 group reduced sharply by pretreatment with Znpp, but the TJ proteins in the LPS þ Znpp group did not show much difference compared with the LPS group. Therefore, the results indicated that Znpp itself cannot change the expression of occludin and ZO-1, and the changes attributed to the expression of HO-1. Our findings are consistent with our study that display RvD1 can protect TJ proteins from disruption by increasing the expression of HO-1. 
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In addition, there is more compelling evidence that increased epithelial/endothelial cell apoptosis contributes to the endothelial and epithelial injury that is characteristic of ALI/ARDS in humans. Studies have shown that ALI is associated with increased cell death in humans, 38 while apoptosis inhibitors showed increased survival rodent models of ALI. 5,39 HO-1-mediated degradation of heme also releases CO. In the sub-toxic amounts produced by HO-1, CO initiates a cyto-protective signaling cascade by inducing the activity of guanylate cyclase to produce cGMP, a second messenger molecule known to protect cells from ischemic damage and enhance cell survival through its action on apoptosis. 40 TNF and other inflammatory mediators have been shown to regulate a variety of additional anti-apoptotic genes, including HO-1. 41 Early study clearly demonstrated that HO-1 induced by NO had a potent anti-apoptotic function in an experimental AH136B solid tumor in rats and Znpp IX induced the apoptosis of AH136B cells both in vivo and in vitro through inhibition of HO-1 activity. 42 HO-1 attenuates glucose-mediated cell growth arrest and apoptosis in human micro-vessel endothelial cells. 43 These may explain why mice pretreated with RvD1 showed higher expression of HO-1 and TJ proteins and decrease of apoptosis cells in TUNEL compared with the LPS group in this study. Moreover, pro-injected with Znpp mice showed more positive cells in TUNEL section compared with LPS þ RvD1 group, but the apoptosis cells in the LPS group proved no marked difference with the LPS þ Znpp group. According to these, RvD1 attenuated apoptosis of epithelial/endothelial cells to protect TJ may be partially due to the pathway of HO-1. In our study, we evaluated the loss of TJ proteins and apoptosis as two parallel results, and the sequence of their happening needs further study. There are many studies on the relationship between them. Su et al 44 demonstrated that apoptosis results in TJ-and MLCK-independent barrier loss; however, Bruewer et al 45 demonstrated that pro-inflammatory cytokines disrupt epithelial barrier function by apoptosisindependent mechanisms.
Conclusion
In summary, this study demonstrated that pretreatment with RvD1 attenuates ALI-induced pulmonary edema and disruption of TJ induced by LPS in mice. In addition, we also demonstrated that RvD1 induce HO-1 and the counteracted effects on the protection role of RvD1 between HO-1 and its antagonist, ZnPP. Therefore, the mechanism of RvD1 attenuating pulmonary edema depends on HO-1. The increasing expression of HO-1 can improve the expression of occludin and ZO-1 and reduce the apoptosis of the epithelial/ endothelial cells to avoid disruption of TJ. But how these procedures are executed needs further study.
